KĀNOLANA: ʻO ke aʻo ʻana i nā kumuhana me ka hypersexuality (porn / addiction addiction) e hōʻike ana i nā loli epigenetic e hoʻohālike ana i nā mea e hele nei ma ka waiʻona. ʻO nā loli epigenetic i pili i nā genes e pili ana me ka pūnaehana oxytocin (ʻo ka mea nui i ke aloha, ka pilina, ka hoʻohui, ke kaumaha, a me nā mea hoʻi). Nā Mīkini:
- ʻO nā māka epigenetic moekolohe / porn addict no ka ʻōnaehana oxytocin o ka lolo ke ʻano like me nā mea ʻona
- Kūlike nā ʻike a Study Kuhn & Gallinat, 2014 (aʻo kaulana FMRI ma luna o nā mea hoʻohana porn)
- Hiki i nā ʻimi ke hōʻike i kahi ʻōnaehana hakihaki disfunctional (ʻo ia kahi loli nui i ka hoʻohui)
- Hoʻololi i ka hoʻololi ʻana i nā hua o oxytocin e pili ana i ka pilina, ke kaumaha, ka hana hoʻonaninani, etc.
No ka hoʻonui hou aku, e heluhelu i kēia ʻatikala ʻōlelo keʻakeʻa: Hōʻike nā ʻepekema ʻepekema i kahi hormone pili i ka maʻi hypersexual
————————————————————————————————————————-
ʻO Adrian E. Boström, Andreas Chatzittofis, Diana-Maria Ciuculete, John N. Flanagan, Regina Krattinger, Marcus Bandstein, Jessica Mwinyi, Gerd A. Kullak-Ublick, Katarina Görts Öberg, Stefan Arver, Helgi B. Schiöth & Jussi Jokinen (2019 )
Nā Epigenetics, DOI: https://doi.org/10.1080/15592294.2019.1656157
Hōʻuluʻulu Manaʻo
Ua manaʻo ʻia ke maʻi Hypersexual (HD) e like me ka maʻi ma ka DSM-5 a me ka papa inoa ʻana 'Compulsive Sexual Behorder Disorder' i kēia manawa ke ʻano he maʻi luhi i ka ICD-11. Hoʻohui ʻia ʻo HD i kekahi mau pūnaehana pathophysiological; komo ka impulsivity, compulsivity, male ʻole ka hoʻowalewale moʻo a me ka hoʻohui hoʻomau. ʻAʻohe noiʻi mua i noiʻi HD i kahi loiloi methylation pili i microRNA (miRNA) pili CpG-mau pūnaewele. ʻO ke kumu methylation ākea ākea i loko o ke koko holoʻokoʻa mai nā kumuhana 60 me nā HD a me 33 olakino olakino e hoʻohana ana i ka Illumina EPIC BeadChip. Ua ʻike ʻia nā kahua ʻo 8,852 miRNA i mau pūnaewele CpG i ka nui o ka loiloi linear regression e pili ana i ka methylation M-waiwai i kahi ʻano kūʻokoʻa kīnā ʻole o ka maʻi maʻi (HD a i ʻole kūleʻa olakino), hoʻoponopono ʻia no nā covariates i koho maikaʻi ʻia. Ua hōʻike ʻia nā pae hōʻike o ka poʻe miRNAs i loko o ia mau mea hoʻokahi no ka loiloi hoʻākāka ʻē aʻe. Ua aʻo hou ʻia ka Candidate methylation loci no kahi hui me ka hilinaʻi ʻana i ka waiʻona i loko o kahi pūʻulu kūʻokoʻa o nā kumuhana 107. ʻElua mau pūnaewele CpG i palena nui i ka HD - cg18222192 (MIR708) (p <10E-05,pFDR = 5.81E-02) a me cg01299774 (MIR4456) (p <10E-06, pFDR = 5.81E-02). Ua hōʻike haʻahaʻa ʻia ʻo MIR4456 i HD ma nā univariate ʻelua (p <0.0001) a me nā aniani multivariate (p <0.05). Ua hoʻopili kūlike ʻia nā pae methylation Cg01299774 me nā pae hōʻike o MIR4456 (p <0.01) a ua methylated ʻokoʻa hoʻi i ka hilinaʻi waiʻona (p = 0.026). Ua hōʻike ʻia ka wānana kuhi a me ka hōʻuluʻulu ʻana i ke ala e hōʻike ana ʻo MIR4456 i nā genes i hōʻike nui ʻia i ka lolo a pili pū kekahi i nā hana molonaola nui i manaʻo ʻia e pili ana no HD, e laʻa, ke ala hōʻailona oxytocin. I ka hōʻuluʻulu manaʻo, hoʻopili kā mākou noiʻi i kahi hāʻawi kūpono o MIR4456 i ka pathophysiology o HD e ke kau ʻana i ka hōʻailona oxytocin.
LEHOLO KA MEA KULA
Ma kahi hui DNA methylation hui i loko o ke koko peripheral, ʻike mākou i nā ʻokoʻa kūkaʻāina o CpG i pili i ka MIR708 a me MIR4456 ka mea e like me ka methylated a me nā maʻi HD. Eia kekahi, hōʻike mākou i ka hsamiR- 4456 e pili ana i ka methylation locus cg01299774 ka meaʻokoʻa a me ka methylated i ka hilinaʻi i ka waiʻona, e hōʻike ana e pili paha ka pili me ka mea hoʻohui i ʻike ʻia ma HD.
I ko mākou ʻike, ʻaʻohe pepa i hōʻike mua i ka pono o MIR4456 ma kahi o ka psychopathologies. Hoʻomaopopo mākou i kēia miRNA e hoʻokuʻi ʻia me ka nānā pono ʻana i ka pūnaehana papa mua a ua wānana i nā kūkulu kekona hulina i ka wā i hele mai ai nā primates. Eia kekahi, hāʻawi mākou i nā hōʻike hōʻike e hoʻokomo ʻia ana nā target mRNA o MIR4456 i makemake ʻia i amygdala a me nā hippocampus, ʻelua mau wahi lolo i manaʻo ʻia e Kühn et al. e hoʻokomo i ka pathophysiology o HD [5].
ʻO ke komo ʻana o ka ala e kau ana i ka hala o ka oxytocin i hōʻike ʻia ma kēia noiʻi ʻana e hōʻike nui ʻia i loko o nā ʻano like ʻole o ka wehewehe ʻana i ka HD e like me ka ʻōlelo ʻana a Kafka et al. [1], e like me ka makemake hōʻiliʻili wahine, compulsivity, impulsivity a me ka (male aku). Hoʻokumu nui ʻia e ka nucleus paraventricular o ka hypothalamus a hoʻopuka ʻia e ka pituitary o ka posterior, ka mea koʻikoʻi ʻo oxytocin i ka hoʻopili ʻana i ka pilina a me ka hana i nā kāne kāne a me nā kāne [59]. Murphy et al. i wehewehe i nā kiʻekiʻe kiʻekiʻe i ka wā moe seksual [60]. Burri et al. ua ʻike i ka noi intranasal oxytocin i nā kāne i hopena i ka hoʻonui ʻia o ka pae o ka epinephrine plasma i ka wā o ka hana moepoe a me ke ʻano he mākaʻikaʻe [61]. Hoʻohui ʻia, ua manaʻo ʻia e oxytocin e hoʻokaʻawale i ka hana o nā koina hypothalamic-pituitary-adrenal (HPA) i ka wā o ka minamina. Jurek et al. ka nānā ʻana i ka hana hoʻokalakupua i ka hopena o ka lātcine i hana ʻia ai ka hopena o ka corticotropin-hoʻokuʻu
ʻO nā hoʻololi ʻana i ke ala no ka hoʻohuihui ʻo okstocin i hiki ke wehewehe i ka loaʻa ʻana ma o Chatzittofis et al., Ka mea i nānā iā HPA axis dysregulation i nā kāne me ka maʻi hypersexual [3]. Eia kekahi, hōʻike nā noiʻi e pili ana ka oxytocin i ka pathophysiology o ka obsessive-compulsive disorder [63]. ʻO ka pilina aku o ka oxygentocin me ka ʻōnaehana dopamine, ka HPA-axis a me ka ʻōnaehana pale i alakaʻi i ka postulation e hōʻike ana nā kūʻokoʻa o kēlā me kēia kūlike i nā kiʻekiʻe o ka oxytocin e hoʻohālikelike ana i ka mea e pili ana i ka addiction [64]. ʻOiai ʻo oxytocin i hele mua ma mua o ka hoʻoponopono ʻana i ka launa a me ke kahe e pili ana, ʻo Johansson et al. hōʻike hou i ka hoʻohālikelike ʻana o nā genetic i ka lātena receptor o oxytocin (OXTR) i ka ulu ʻana i ka huli ʻana i nā kūlana me nā kiʻekiʻe kiʻekiʻe o ka huhū ma lalo o ke ʻano o ka waiʻona [65]. ʻO ka mea hope loa, ʻo Brüne et al. hopena i ka loli maoli a OXTR i ka wehewehe ʻana i ka pathophysiology o ka borderline personality disorder [66], kahi ʻano pilikino i hōʻike ʻia e ka maʻi impulsivity dysregulation [66].
Loaʻa ka MIR4456may i kahi hana hoʻoponopono hou aku i ka HD i ʻole i hōʻike ʻia mai i ka hoʻopaʻa ʻana ma kēia manawa. Ma ka laina me kā mākou ʻike, ua hōʻike ʻia nā haʻawina mua i nā hui o ka wahine kāne kāne a me nā ʻano kaomi i komo i ka hoʻopili glutamatergic i loko o nā mea i hoʻopilikia ʻia [67]. Eia kekahi, hiki i kahi hana kūpono o ke kiʻekiʻe 3ʹ-5ʹ-cyclic adenosine mono phosphate (cAMP) i loko o ke komo ʻana i nā kāne i ka nui o nā wahine, ma ka hoʻohuli ʻana i ka phosphoprotein-32 a alakaʻi i nā loli o nā progestin receptors [68]. ʻO ka mea mahalo, ʻo ka cAMP ka hoʻoponopono i nā molekele e pili pū me ka alakaʻi axon [69], e like me ka B3gnt1 gen, ka mea i hui pū me ka wahine kāne i ka waikaole kāne.
PAHANAʻI KAHIKO NĀ MANA:
Hōʻike nā ʻepekema ʻepekema i kahi hormone pili i ka maʻi hypersexual
Ua hōʻike ʻia kahi noi hou o nā kāne a me nā wahine me ka maʻi hypersexual i kahi hiki i ka hormone oxytocin, e like me nā hopena i paʻi ʻia ma ka puke pai. Nā Epigenetics. ^ E Ha yM. Hiki i ka loaʻa ka wehe ʻana i ka puka no ka mālama ʻana i ka maʻi ma o ka ʻenekini ʻana i ke ala e kāohi ai i kāna hana.
ʻO ka maʻi hypersexual, a i ʻole ka wahine holoʻokoʻa neʻe, ua ʻike ʻia he mea hoʻohālikelike lawaiʻa hoʻopiʻi, ka mea i helu ʻia ma kahi ʻano kīʻaha luhi e ka World Health Organization. Hiki ke hoʻohālikelike ʻia i nā manaʻo noʻonoʻo ʻole o ka moekolohe, kahi koi i hana i nā hana moekolohe, kahi nele o ka hoʻokele, a me nā hana pilikino e hāpai i nā pilikia a i ʻole nā hopena kūlike. ʻOiai nā koho hoʻohālike e like me ka ʻano o ka pākuʻi, hōʻike ʻia nā puke e pili ana ka maʻi hypersexual i ka 3-6% o ka lehulehu.
Ka puni ʻana o ka maʻi i ka maʻi maʻamau no ka mea e hele pinepine ʻia ana me ia i nā pilikia olakino ʻē aʻe, e hōʻike ana he mea hiki ke hoʻonui i kahi hoʻomāʻike ʻia paha i ke ʻano noʻonoʻo. Ua ʻike ʻia kahi mea liʻiliʻi e pili ana i ka neurobiology ma hope.
"Ua hele mākou e nānā i nā ʻano hana epigenetic ma hope o ka maʻi hypersexual i hiki ai iā mākou ke hoʻoholo inā loaʻa kekahi mau hiʻohiʻona e hoʻokaʻawale iā ia mai nā pilikia olakino ʻē aʻe," i ʻōlelo ʻia e ka mea kākau alakaʻi ʻo Adrian Boström mai ka ʻOihana Neuroscience ma Uppsala University, Suetena nāna i alakaʻi ka hoʻopaʻa me nā kānaka noiʻi mai ka Andrology / Sexual Medicine Group (ANOVA) ma Karolinska Institutet, Stockholm, Suède.
"I ko mākou ʻike, ʻo kā mākou noi ʻana ka mea mua e hoʻopili i nā epigenetic dysregulatedʻano papa hana o ka DNA methylation a me ka hana microRNA a me ke komo ʻana o ka oxytocin i ka lolo i waena o nā mea maʻi e ʻimi nei i ka moekolohe."
Ua ana nā kānaka ʻepekema i nā hiʻohiʻona DNA methylation i loko o ke koko mai nā mea maʻi 60 me ka maʻi hypersexual a hoʻohālikelike iā lākou i nā hoʻohālike mai 33 mau mea ola olakino.
Ua noiʻi lākou i nā wahi ʻo 8,852 o ka DNA methylation e pili ana i nā microRNA e kokoke ana e ʻike i nāʻokoʻa like ma waena o nā hoʻohālike. Hiki i ka methylation DNA ke hoʻopilikia i ka hōʻike gen a me ka hana o nā ʻano genes, i ka hana maʻamau e hōʻemi i kā lākou hana. Kahi i ʻike ʻia ai nā loli i ka DNA methylation, ua noiʻi nā mea noiʻi i nā pae o ka hōʻike o ka gen o ka microRNA pili. He mea hoihoi loa nā MicroRNAs i ka mea hiki iā lākou ke kau i ke kahe-lolo-lolo a hoʻololi a hoʻonāukiuki i ka hōʻike ʻana a hiki i nā haneli he mau kānaka o ka umauma a me nā kikoʻī.
Hoʻohālikelike lākou i kā lākou ʻike ʻana i nā hoʻohālike mai nā kumuhana 107, 24 nona ka inu ʻona, e makaʻala i kahi hui me ka hana hoʻohalike.
Ua hōʻike nā hopena i ʻelua mau wahi o ka DNA i hoʻololi ʻia i nā maʻi maʻi hypersexual. Ua hoʻoneʻe ʻia ka hana maʻamau o ka methylation DNA a ua hoʻopili ʻia kahi microRNA e pili ana, i komo pū ʻia me ka silencing gene, i ʻike ʻia ma lalo o ka ʻōlelo. Hōʻike ka loiloi ua ʻike ʻia ka microRNA, microRNA-4456, ke kuhi i nā gen i hōʻike ʻia i nā kiʻekiʻe kiʻekiʻe o ka lolo a pili i nā hoʻoponopono o ka hormone oxytocin. Me ka hoʻohaʻahaʻa ʻana i ka gen, ua ʻōlelo ʻia paha ka oxygentocin e piʻi i ke kiʻekiʻe kiʻekiʻe, ʻoiai ke hōʻoia nei ka hoʻopaʻa ʻana o kēia mau mea i kēia.
Ua ʻike ʻia ia ma nā vole kikoʻī a me nā mea kikowaena ulu o ka neuropeptide oxytocin e hana nui i ka rula o ka hana pālua. Ua hōʻike ʻia nā haʻawina mua e pili ana ka oxytocin i ka hoʻoponopono ʻana i ka launa pū ʻana a me ka hana a ka lua, ka lua a me ka wahine a me nā wahine. ʻO ka hoʻohālikelike ʻana me nā kumuhana e pili ana i ka waiʻona ua hōʻike i ka like me ka like o ka mea like me ka mea nui o ka maʻi hypersexual, e like me ka mea i pili i ka wahine, makemake ʻia a me ka wahine hoʻokalakupua.
"Pono ʻia kahi noiʻi hou e noiʻi i ke kuleana o microRNA-4456 a me ka oxytocin i loko o ka maʻi hypersexual, akā ʻo kā mākou hopena e hōʻike ana he mea kūpono ke nānā i nā pono o ka lāʻau a me ka psychotherapy e hoʻemi i ka hana o ka oxytocin," wahi a Professor Jussi Jokinen mai Umeå Kulanui, Kuekene.
Ua kākau nā mea kākau i kahi palena o ka ʻikepili, ʻo ke ʻano ka hoʻohālikelike o ka methylation DNA ma waena o nā maʻi maʻi hypersexual a me nā mea hana olakino e noho kokoke ana a ma 2.6%, no laila ke kapa ʻia ka hopena i nā loli physiological. Eia nō naʻe, kahi ulu kino o nā hōʻike hōʻike e hiki i nā loli methylation maʻalahi wale nō ke loaʻa i nā hopena ākea no nā kūlana paʻakikī e like me ke kaumaha a i ʻole ka schizophrenia.
###
Hoʻonohonoho ʻia ka haʻawina ma waena o ka ʻaha kuʻina kūloko ma waena o ke Kulanui o Umeå me Västerbotten County Council (ALF) a me nā mea i hāʻawi ʻia e ka ʻĀkana ʻo Stockholm i makemake ʻia e ka Swedish Research Foundation, ka Åhlens Foundation, ka Novo Nordisk Foundation, a me ka Swedish Brain Research Pūnaewele.
KA MOOLELO KULA
Nā Hoʻololi Epigenetic i pili i ka Hypersexual Disorder a me nā Hana Hoʻohui
Nīnauele ʻo MedicalResearch.com me: Adrian E. Boström MD, no ke kumu o nā mea kākau
Keena o Neuroscience, ke Kulanui ʻo Uppsala, Suetena
MedicalResearch.com: He aha ke ʻano o kēia noi?
Pane: ʻOiai nā koho hoʻohālike e like me ka ʻano o ka pākuʻina, hōʻike ʻia nā puke e pili ana ka maʻi hypersexual (HD) i ka 3-6% o ka heluna o ka lehulehu. Eia nō naʻe, puni ka hoʻonāukiuki i ka maʻi maʻi a liʻiliʻi iki i ʻike e pili ana i ka neurobiology ma hope.
ʻAʻole i hoʻokolokolo mua ʻia ka maʻi ʻo hypersexual e pili ana i ka epigenomic a me nā transcriptomics i kahi kuhi noiʻi manuahi-ʻole a ʻike iki ʻia e pili ana i ka neurobiology ma hope o kēia maʻi. Nānā mākou inā aia kekahi mau hoʻololi epigenetic e pili ana i ka hana a me ka haʻi ʻana i nā maʻi hypersexual (HD) a ʻike ʻia kahi microRNA disregulated i manaʻo ʻia e hoʻohuli i ka hana o ka hormone oxytocin i ka lolo.
ʻIke ʻia ʻo Oxytocin e loaʻa nā ʻano laha ākea ākea. I ka maikaʻi o kā mākou ʻike, ʻaʻohe noiʻi i hāʻawi ʻia i hōʻike no ka hui ma waena o DNA methylation, hana microRNA a me ka oxytocin i ka maʻi hypersexual. Kūpono kā mākou mea i loaʻa hou i ka noiʻi ʻana i ke kuleana o MIR4456 a ʻoi loa ʻo Oxytocin i ka maʻi hypersexual. Pono nā noiʻi hou e hōʻoia i ka hana o Oxytocin i HD a e nānā inā paha he hopena maikaʻi ka lāʻau me ka oxytocin antagonist drug therapy no nā mea maʻi e ʻeha ana i ka maʻi hypersexual.
MedicalResearch.com: He aha nā ʻike nui?
Pane: - Ma kēia noiʻi ua noiʻi ma luna o 8000 ʻokoʻa DNA Methylation i hoʻomaka ʻia i loko o kahi hypotesa-free a me kahi ʻano like ʻole. No laila mākou i pīhoihoi a pīhoihoi i ka ʻike ʻana i ke ʻano microRNA hiki i ke kūmākena i hoʻohālikelike ʻia i nā ʻano kiko i hōʻike ʻia i loko o ka lolo a ua komo i nā ʻano molekine neuronal nui i manaʻo ʻia he kūpono loa no ka maʻi hypersexual, e laʻa, a ʻo ke alima e kuhi ana. Me kēia microRNA ʻike ʻia he evolutionary mālama ʻia ma loko o nā primata, a he mea hoihoi a ʻike ʻole ʻia hoʻi ia.
MedicalResearch.com: He aha nā mea heluhelu e lawe aku ai i kāu hōʻike?
Pane: Hoʻopili ka maʻi hypersexual i nā ʻano hana like pathophysiological a me ke ʻano impulsivity, compulsivity, ʻimi hoʻonaʻauao wahine a me ka male ʻana. Hiki ke hoʻākāka ʻia kēia mea i ka maʻi kūlohelohe o ka hypersexual, akā ʻaʻole e ʻike ʻia he addiction. ʻO kā mākou mau mea ʻike, ma ka māmā o ka crossover me ka hilinaʻi i ka waiʻona, hōʻike i ka MIR4456 a me ke ala no ka hōʻailona hōʻailona o ka oxytocin e pili pū me ka mea hoʻohui i ke ʻano o ka maʻi hypersexual. Pono nā noi hou e hōʻoiaʻiʻo i kēia.
MedicalResearch.com: He aha nā ʻōlelo āu e noi ai no ka noiʻi ʻana ma hope o kēia hana?
Pane: Hoʻoikaika kā mākou hopena i ka noiʻi hou ʻana i ka pono o, no ka laʻana, oxytocin e hoʻoponopono ana i ka lāʻau lāʻau i ka maʻi hypersexual i hiki ke kōkua i nā koho lapaʻau hou e hoʻomaikaʻi ai i ka hopena maʻi o ka poʻe i hoʻopilikia ʻia. Eia hou, ʻike mākou i kahi microRNA kikoʻī (miRNA) kahi e hiki ai ke hōʻoia ʻia ka miRNA hiki ke hoʻoponopono ʻia nā lāʻau i ka maʻi hypersexual.
MedicalResearch.com: He mea ʻē aʻe āu e makemake e hoʻohui?
Pane: ʻO kā mākou DNA kahi code genetical no nā genes i unuhi i nā kaʻina ʻokoʻa o nā amino acid i kapa ʻia nā protein. ʻO nā Proteins ka mea i wehewehe nui i nā mea ola āpau. Ua hoʻoili ʻia kā mākou DNA a ʻaʻole e loli i ka holo ʻana o ka manawa. Akā, pili kēia aʻo ʻana i nā epigenetics, nā loli e hoʻopili i ka hana a me ka haʻi. Hoʻololi kēia mau hana epigenetic i ka manawa a hiki ke disregulated i kekahi mau maʻi. Aia kekahi mau ʻano epigenetic.
I loko o kēia noi ʻana, ua aʻo mākou i ka methylation DNA (kahi hana i ʻike ʻia e hoʻohuli ai i ka hōʻike o ka ʻaoʻao, ʻo ia hoʻi, ka nui o kahi ʻāpana i unuhi ʻia i loko o kahi protein) a me ka hana microRNA (nā ʻāpana gen non-coding liʻiliʻi i hiki ke hoʻohuli i ka unuhi o kekahi mau haneli. nā gen ʻokoʻa).
Ke hoʻohālikelike nei i nā mea maʻi me ka maʻi hypersexual i nā mea manawaleʻa olakino, ʻike mākou i kahi kaʻina methylation DNA e loli nui ʻia i ka maʻi hypersexual. No ka ʻike ʻana i ke koʻikoʻi o kēia loaʻa ʻana, ua hōʻike hou ʻia ke kaʻina DNA like e hoʻokaʻawale ʻia i nā kumuhana me ka hilinaʻi ʻana o ka waiʻona, e ʻōlelo nei hiki ke pili mua ʻia me ka mea hoʻohui o ka maʻi hypersexual. ʻO ke kaʻina methylation DNA i ʻike ʻia e pili ana i kahi microRNA i kapa ʻia (microRNA 4456; MIR4456), a ua hōʻike hou ʻia ka hōʻike ʻana e pili ana kēia kaʻina methylation DNA i ka nui o MIR4456 i hana ʻia. Eia kekahi, i ka hui like like, hōʻike mākou i ka MIR4456 i ka nui haʻahaʻa o ka maʻi hypersexual i ka hoʻohālikelike ʻia me nā mea manawaleʻa olakino, e ʻōlelo ikaika nei i ka hoʻololi ʻana o nā methylation DNA i nā ʻano maʻi hypersexual a kōkua i ka wehewehe ʻana i ka disregulation i ʻike ʻia o MIR4456. Ma ke ʻano he microRNA: hiki ke hoʻokumu i nā genes like ʻole he haneli, ua hoʻohana mākou i nā algorithms kamepiula e hōʻike i ka MIR4456 pahuhopu i nā genes e hōʻike maikaʻi ʻia i ka lolo a pili i nā hana molonalona nui i manaʻo ʻia e pili ana no HD, e laʻa, ka oxytocin ala hōʻailona. Kūpono kā mākou mea i loaʻa hou i ka noiʻi ʻana i ke kuleana o MIR4456 a ʻoi loa ʻo Oxytocin i ka maʻi hypersexual. Pono nā noiʻi hou e hōʻoia i ke kuleana o Oxytocin i HD a e nānā inā he hopena maikaʻi me ka oxytocin antagonist drug therapy i nā maʻi e loaʻa ana i ka maʻi hypersexual.
Akā, ʻaʻole i paʻi ʻia ka ʻikepili i manaʻo ʻia no kahi noiʻi ʻimi ʻokoʻa e hōʻike i ka hoʻonui nui ʻana o nā pae Oxytocin i nā mea maʻi me ka maʻi hypersexual ke hoʻohālikelike ʻia i nā kaohi, a me ka hōʻemi nui ʻana i nā pae oxytocin ma hope o ka mālama ʻana o Cognitive Behaviour Therapy, e hōʻike ikaika nei i kahi kuleana o Oxytocin i ka maʻi hypersexual a ke hana nei i nā kuleana i hōʻike ʻia i loko o kēia aʻo ʻana i ʻoi aku ka ikaika. Ua hōʻike ʻia kēia mau hopena mua ma ke ʻano he pepa haki wāwahi ma ka hālāwai o Society of Biological Psychiatry ma Mei 2019 a waiho ʻia hoʻi ma ke ʻano he pepa i ACNP i Kekemapa 2019.
Hōʻike:
ʻO Adrian E. Boström et al, Hypermethylation e pili ana i ka hoʻoneʻe ʻana o ka microRNA-4456 i ka maʻi hypersexual me ka hopena makeative ma ka oxytocin hōʻailona, kahi hōʻike DNA methylation o nā gen miRNA, Nā Epigenetics (2019). DOI: 10.1080 / 15592294.2019.1656157
;
